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PDE3B by the protein kinases IKKε and 
TBK1
Jonathan Mowers1,2,3†, Maeran Uhm1,2,3†, Shannon M Reilly1, Joshua Simon1, Dara 
Leto1‡a, Shian-Huey Chiang1‡b, Louise Chang1, Alan R Saltiel1,2,3*
1Life Sciences Institute, University of Michigan, Ann Arbor, United States; 
2Department of Internal Medicine, University of Michigan, Ann Arbor, United States; 
3Department of Molecular and Integrative Physiology, University of Michigan, Ann 
Arbor, United States
Abstract Obesity produces a chronic inflammatory state involving the NFκB pathway, resulting in 
persistent elevation of the noncanonical IκB kinases IKKε and TBK1. In this study, we report that 
these kinases attenuate β-adrenergic signaling in white adipose tissue. Treatment of 3T3-L1 
adipocytes with specific inhibitors of these kinases restored β-adrenergic signaling and lipolysis 
attenuated by TNFα and Poly (I:C). Conversely, overexpression of the kinases reduced induction of 
Ucp1, lipolysis, cAMP levels, and phosphorylation of hormone sensitive lipase in response to 
isoproterenol or forskolin. Noncanonical IKKs reduce catecholamine sensitivity by phosphorylating 
and activating the major adipocyte phosphodiesterase PDE3B. In vivo inhibition of these kinases by 
treatment of obese mice with the drug amlexanox reversed obesity-induced catecholamine 
resistance, and restored PKA signaling in response to injection of a β-3 adrenergic agonist. These 
studies suggest that by reducing production of cAMP in adipocytes, IKKε and TBK1 may contribute 
to the repression of energy expenditure during obesity.
DOI: 10.7554/eLife.01119.001
Introduction
Obesity generates a state of chronic, low-grade inflammation in liver and adipose tissue accompanied 
by macrophage infiltration and the local secretion of inflammatory cytokines and chemokines that 
attenuate insulin action, resulting in insulin resistance and the subsequent development of Type 2 
diabetes (Wellen and Hotamisligil, 2005; Hotamisligil, 2006; Lumeng et al., 2007; Shoelson et al., 
2007). Numerous studies indicate a strong correlation between inflammation and insulin resistance 
across several populations (Hotamisligil, 2006). Moreover, genetic ablation or pharmacological inhi-
bition of inflammatory pathways can dissociate obesity from insulin resistance (Hotamisligil, 2006; 
Shoelson et al., 2007), suggesting that local inflammation can be a key step in the generation of insulin 
resistance.
The transcription factor NFκB and its inflammatory program play an important role in the develop-
ment of insulin resistance in obese liver and adipose tissue (Yuan et al., 2001; Arkan et al., 2005; 
Wunderlich et al., 2008; Chiang et al., 2009). NFκB is activated by the IκB kinase (IKK) family, which 
has four members: IKKα, IKKβ, IKKε, and TBK1. IKKα and IKKβ act with the scaffolding partner NEMO 
to activate NFκB (Hacker and Karin, 2006). Although pharmacologic inhibition or genetic ablation of 
IKKβ defined a role for this kinase in insulin resistance (Yuan et al., 2001; Arkan et al., 2005), the roles 
of the noncanonical kinases IKKε and TBK1 are less certain.
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We recently reported that both mRNA and protein expression levels of IKKε and TBK1 are increased 
in adipose tissue from mice fed a high fat diet (Chiang et al., 2009). Both of these kinases are increased 
as a consequence of the inflammatory program in obesity (Reilly et al., 2013), and contain NFκB reg-
ulatory sites in their promoter regions, allowing them to be induced upon NFκB activation (Kravchenko 
et al., 2003). Deletion of the IKKε gene rendered mice partially resistant to some of the deleterious 
effects of high fat feeding, including weight gain, insulin resistance, hepatic steatosis, and systemic 
inflammation (Chiang et al., 2009). We report, in this study, that IKKε and TBK1 can desensitize lipolytic 
signaling in white adipose tissue in response to β-adrenergic agonists by phosphorylating and increasing 
the activity of PDE3B, in the process decreasing cAMP levels. Thus, induction of these noncanonical 
IκB kinases might contribute to catecholamine resistance during obesity, and blocking their activity has 
the potential to increase energy expenditure as an anti-obesity and anti-diabetes therapy.
Results
IKKε and TBK1 overexpression decrease sensitivity to the β-adrenergic/
cAMP pathway in 3T3-L1 adipocytes
Sympathetic activation of adipose tissue plays a key role in maintaining energy balance by stimulating 
lipolysis and fat oxidation (Coppack et al., 1994; Langin, 2006; Festuccia et al., 2011). Activation of 
β-adrenergic signaling by either β-adrenergic agonists or cold exposure in white and brown adipose 
tissue initiates a cascade of events through cyclic AMP (cAMP), culminating in the transcriptional 
upregulation of Ucp1, which results in increased proton leak and energy expenditure (Himms-Hagen 
et al., 2000; Cao et al., 2004; Yehuda-Shnaidman et al., 2010). Our previous studies revealed that 
compared to wild-type (WT) controls, IKKε-deficient mice exhibited increased energy expenditure 
while on a high fat diet (HFD), accompanied by increased expression of Ucp1 in white adipose depots 
(Chiang et al., 2009). Interestingly, increased energy expenditure in IKKε-deficient mice was only seen 
in HFD-fed mice (Chiang et al., 2009), suggesting that upon induction of IKKε during obesity, the 
eLife digest Obesity is a complex metabolic disorder that is caused by increased food intake 
and decreased expenditure of energy. Obesity also increases the risk of developing type 2 diabetes, 
heart disease, stroke, arthritis, and certain cancers. There is considerable evidence to suggest that 
adipose tissue becomes less sensitive to catecholamines such as adrenaline in states of obesity, and 
that this reduced sensitivity in turn reduces energy expenditure. However, the details of this process 
are not fully understood.
It is well established that obesity generates a state of chronic, low-grade inflammation in liver 
and adipose tissue, accompanied by the secretion of signaling proteins that prevent fat cells from 
responding to insulin, which leads to type 2 diabetes. Activation of the NFκB pathway is thought to 
have a central role in causing this inflammation. Now Mowers et al. have investigated whether 
inflammation caused by activation of the NFκB pathway also has a role in producing catecholamine 
resistance in fat cells.
Obesity-dependent activation of the NFκB pathway increases the levels of a pair of enzymes, 
IKKε and TBK1. Mowers et al. found that elevated levels of these two enzymes reduced the ability 
of certain receptors (called β-adrenergic receptors) in the fat cells of obese mice to respond to 
catecholamines. High levels of the two enzymes also resulted in lower levels of a second messenger 
molecule called cAMP, which increases energy expenditure by elevating fat burning. However, 
treating the fat cells with drugs that interfere with the two enzymes restored sensitivity to 
catecholamine, allowing the fat cells to burn energy.
Mowers et al. also treated obese mice with amlexanox, a drug that inhibits these enzymes, and 
found that this treatment made the mice sensitive to a synthetic catecholamine that triggered the 
release of energy from fat. Mowers et al. suggest, therefore, that IKKε and TBK1 respond to 
inflammation in the body by reducing catecholamine signaling, thus preventing energy expenditure. 
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kinase might repress an increased adaptive thermogenic response to overnutrition. To explore this 
possibility, we overexpressed IKKε in 3T3-L1 adipocytes and examined Ucp1 gene expression after 
treatment with the non-selective β-adrenergic agonist, isoproterenol (ISO), or the β3-adrenergic agonist, 
CL-316,243. Fold difference in Ucp1 gene expression was calculated by normalization of relative Ucp1 
mRNA levels in treated relative to control samples. Treatment of empty vector-expressing cells with 
ISO or CL-316,243 resulted in a 1.6-fold or twofold increase in Ucp1 mRNA levels, respectively (Figure 1A). 
Figure 1. IKKε and TBK1 overexpression decrease sensitivity to the β-adrenergic/cAMP pathway in 3T3-L1 adipocytes. 
(A) Fold increase in Ucp1 expression in 3T3-L1 adipocytes expressing empty vector, Flag-IKKε, or Flag-IKKε K38A 
following treatment with or without 10 μM ISO (black bars) or 10 μM CL-316,243 (CL, gray bars) for 4 hr. **p<0.01. 
Performed in triplicate. (B) Glycerol release from 3T3-L1 adipocytes expressing empty vector (white bars), Flag-IKKε 
(black bars), or Flag-IKKε K38A (gray bars) treated with or without 10 μM ISO or 10 μM CL. *p<0.05 and **p<0.01. 
Performed in triplicate. (C) Immunoblots of whole cell lysates from Figure 1B. Results were replicated in triplicate. 
D.E. stands for dark exposure and L.E. stands for light exposure. (D) Immunoblots of whole cell lysates from 3T3-L1 
adipocytes expressing empty vector or Flag-IKKε treated with or without 50 μM FSK for 15 min. Results were replicated 
in multiple experiments. (E) cAMP levels from 3T3-L1 adipocytes expressing empty vector, Flag-IKKε, or Flag-IKKε K38A 
treated with or without 10 μM ISO or 50 μM FSK for 15 min. **p<0.0001 and *p<0.05. Performed in triplicate.
DOI: 10.7554/eLife.01119.003
The following figure supplements are available for figure 1:
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The induction of Ucp1 gene expression in response to ISO or CL-316,243 was blunted when WT IKKε 
was overexpressed in these cells. However, expression of the kinase-inactive mutant of IKKε K38A 
(Fitzgerald et al., 2003) was less effective, but still modestly repressed Ucp1 expression.
In addition to increased Ucp1 expression, IKKε knockout mice also exhibited increased lipolysis and 
fat oxidation (Chiang et al., 2009), suggesting that decreased lipolysis in adipose tissue from obese 
mice might result in part from increased expression of IKKε and TBK1 (Chiang et al., 2009). We thus 
modeled the obesity-dependent increase in the noncanonical IKKs by overexpressing IKKε in 3T3-L1 
adipocytes, followed by assay of glycerol release in response to ISO or CL-316,243. Although both isopro-
terenol and CL-316,243 increased lipolysis in empty vector-expressing cells, overexpression of WT IKKε 
reduced the lipolytic effects of isoproterenol and CL-316,243 by greater than 40%, and also reduced 
basal glycerol release (Figure 1B). The reduction in lipolysis by IKKε overexpression was accompanied by 
dramatically reduced phosphorylation of HSL and perilipin in response to ISO or CL-316,243 (Figure 1C). 
Expression of the catalytically inactive kinase was less effective in blocking lipolytic signaling, although 
the levels of protein achieved by overexpression were lower compared to the WT kinase (Figure 1B,C, 
Figure 1—figure supplement 1A). Overexpression of TBK1 reduced phosphorylation of HSL in response 
to isoproterenol or the adenylyl cyclase activator, forskolin (Figure 1—figure supplement 1B). Identical 
results were obtained when IKKε was overexpressed in 3T3-L1 adipocytes stimulated with forskolin 
(Figure 1D), as detected by western blotting with an anti-phospho-PKA substrate motif antibody. 
Overexpression of IKKε also repressed the phosphorylation of p38 (p-p38) in response to forskolin 
(Figure 1D) or isoproterenol (Figure 1—figure supplement 1A), whereas overexpression of IKKε 
K38A was without effect (Figure 1—figure supplement 1A). While glycerol release is likely the 
result of changes in HSL and perilipin phosphorylation, it is important to note that we have not 
directly assayed whether re-esterification of glycerol intermediates are also affected. Taken together, 
these data suggest that similar to what is observed in obesity, overexpression of IKKε or TBK1 can 
repress lipolytic signaling. The partial effectiveness of the kinase-inactive mutants is puzzling, but 
may reflect their activation of endogenous IKKε or TBK1 kinases due to dimerization (Larabi et al., 
2013; Tu et al., 2013).
Since PKA signaling is responsible for Ucp1 induction in response to catecholamines (Klein et al., 
2000; Cao et al., 2001), we explored the possibility that both IKKε and TBK1 might reduce β-adrenergic 
sensitivity of adipocytes by decreasing cAMP levels. IKKε overexpression in 3T3-L1 adipocytes reduced 
by greater than 80% the increase in cAMP levels produced by both isoproterenol and forskolin, 
whereas overexpression of IKKε K38A did not (Figure 1E). Previous studies have shown that decreased 
sensitivity to adrenergic stimuli in adipose tissue can result from reduced β-adrenergic receptors 
(Reynisdottir et al., 1994) or increased expression of α2-adrenergic receptors (Stich et al., 2002). 
These studies represent the first demonstration that defects distal to the adrenergic receptor may also 
contribute to catecholamine resistance, and suggest that IKKε and TBK1 can attenuate the β-adrenergic/
cAMP pathway in response to β-adrenergic stimuli in adipocytes in a cell-autonomous manner, and 
further that induction of these kinases during obesity may account for decreased energy expenditure 
by reducing sensitivity of adipocytes to β-adrenergic stimulation.
Prolonged treatment with TNFα decreases the sensitivity of adipocytes 
to β-adrenergic stimulation in a manner dependent on the activity of 
IKKε and TBK1
Obesity is accompanied by infiltration of proinflammatory macrophages into adipose tissue; these 
cells secrete inflammatory cytokines, such as TNFα, which generate insulin resistance by stimulating 
catabolic pathways (Hotamisligil, 2006; Lumeng et al., 2007; Ye and Keller, 2010; Ouchi et al., 
2011). Although TNFα is known to increase lipolysis in adipocytes (Zhang et al., 2002; Souza et al., 
2003; Green et al., 2004; Plomgaard et al., 2008), there is also evidence of a counterinflammatory 
response in obesity that may serve to repress energy expenditure (Gregor and Hotamisligil, 2011; 
Saltiel, 2012; Calay and Hotamisligil, 2013; Reilly et al., 2013). We thus used TNFα to model the 
inflammatory milieu of obese adipose tissue in cell culture to determine whether the cytokine might 
also regulate β-adrenergic signaling in this context. While short-term treatment with TNFα augmented 
the increase in cAMP produced by forskolin treatment, this effect declined after 12 hr. After 24 hr of 
exposure, TNFα inhibited the production of the second messenger produced by forskolin (Figure 2—
figure supplement 1A). Thus, the catabolic effects of the proinflammatory cytokine TNFα in adipocytes 
are transient and followed by an inhibitory phase.
Cell biology
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Our previous studies revealed that treatment of 3T3-L1 adipocytes with TNFα for 24 hr induced the 
expression of IKKε and increased TBK1 phosphorylation at the active site in a manner that was 
dependent on the activity of IKKβ and the NFκB pathway (Reilly et al., 2013). We thus wondered 
whether the repression of β-adrenergic sensitivity produced by longer-term treatment with TNFα might 
be due to increased activity of the noncanonical IKKs. Long-term treatment with TNFα repressed the 
induction of Ucp1 gene expression in response to β-adrenergic stimuli (Figure 2—figure supplement 
1B), whereas the expression of IKKε mRNA (Ikbke) was upregulated, as previously reported (Reilly et al., 
2013). Treatment of 3T3-L1 adipocytes with TNFα for 24 hr decreased glycerol release in response to 
both isoproterenol and forskolin in a dose-dependent manner (Figure 2A). TNFα treatment also 
decreased isoproterenol- and forskolin-stimulated cAMP production; an effect that was largely rescued 
by preincubation of cells with the selective, but structurally unrelated inhibitors of IKKε and TBK1, 
amlexanox (Figure 2B) (Reilly et al., 2013) or CAY10576 (Figure 2C) (Bamborough et al., 2006).
Isoproterenol-stimulated β-adrenergic signaling was also decreased by treatment of cells with 
TNFα (Figure 2D), as manifested by decreased phosphorylation of HSL, perilipin, and other proteins 
recognized by the PKA substrate motif antibody, whereas IKKε expression was concurrently upregulated 
and TBK1 phosphorylation was increased by the treatment with TNFα. Pretreatment of 3T3-L1 adipocytes 
with amlexanox also blocked the inhibitory effect of TNFα on isoproterenol-stimulated β-adrenergic 
signaling, as determined by western blotting with an anti-phospho-PKA substrate motif antibody, anti-
phospho-HSL, and anti-phospho-perilipin antibodies (Figure 2E). Interestingly, phosphorylation of 
p38 in response to isoproterenol was also dramatically augmented by amlexanox in a dose-dependent 
manner. Previous studies showed that the toll-like receptor 3 (TLR3) agonist, Poly (I:C), results in the 
direct activation of IKKε and TBK1 (Hemmi et al., 2004; Clark et al., 2009; Clark et al., 2011). Similar 
to TNFα, treatment of 3T3-L1 adipocytes with Poly (I:C) simultaneously reduced stimulation of cAMP 
production, lipolysis and phosphorylation in response to β-adrenergic stimulation (Figure 2—figure 
supplement 1C–E), and the inhibitory effects of Poly (I:C) on the sensitivity to isoproterenol stimulation 
were partially restored by amlexanox pretreatment, but not to the extent that was observed with TNFα 
treatment (Figure 2E). It is possible that Poly (I:C)-induced desensitization of β-adrenergic pathway 
engages other pathways that are not directly regulated by IKKε and TBK1. These results suggest that 
obesity-associated inflammation leads to the activation of IKKε and TBK1, which produces reduced 
sensitivity of adipocytes to β-adrenergic stimulation.
IKKε and TBK1 reduce cAMP levels through activation of PDE3B
cAMP levels can also be regulated by phosphodiesterases, which cleave the second messenger and in 
the process dampen cAMP-dependent signals. Phosphodiesterase 3B (PDE3B) is the major PDE 
isoform expressed in adipocytes (Zmuda-Trzebiatowska et al., 2006). Genetic ablation or pharmaco-
logical inhibition of PDE3B in cells and in vivo revealed an important role for the enzyme in lipid and 
glucose metabolism (Choi et al., 2006; Berger et al., 2009; Degerman et al., 2011). Phosphorylation 
and activation of PDE3B by insulin in adipocytes is thought to be mediated by Akt, and cAMP itself 
acts as a negative feedback regulator of its own levels by promoting PKA-dependent phosphorylation 
and activation of PDE3B (Degerman et al., 2011).
Since we observed that cAMP production was impaired in forskolin or isoproterenol-stimulated 
3T3-L1 adipocytes overexpressing IKKε (Figure 1E), we examined whether noncanonical IKKs might 
desensitize adrenergic stimulation through increased activity of PDE3B in adipocytes. Pretreatment 
with a nonspecific phosphodiesterase inhibitor, IBMX, in 3T3-L1 adipocytes expressing IKKε or TBK1 
rescued the full stimulation of cAMP production in response to forskolin (Figure 3A). Interestingly, the 
selective PDE3B and PDE4 inhibitor, Zardaverine (Schudt et al., 1991), also blocked the inhibitory 
effects of IKKε and TBK1 overexpression on cAMP levels in response to isoproterenol and forskolin in 
3T3-L1 adipocytes (Figure 3B), suggesting an important role for PDE3B as a target of the noncanonical 
IKKs.
We next examined whether IKKε and TBK1 directly phosphorylate PDE3B to regulate cAMP levels. 
Recombinant TBK1, Akt and PKA were incubated in vitro with [γ- 32P]ATP and purified PDE3B as a 
substrate. Phosphorylation was assessed by SDS-PAGE followed by autoradiography. TBK1 directly 
catalyzed the phosphorylation of PDE3B; phosphorylation was also produced by incubation with Akt 
and PKA, as previously reported (Kitamura et al., 1999; Palmer et al., 2007) (Figure 3C). IKKε also 
catalyzed this phosphorylation in vitro (data not shown). This increase in phosphorylation produced by 
in vitro incubation with TBK1, IKKε and PKA was also detected when PDE3B was blotted with antibodies 
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that recognize the 14-3-3 binding motif (Figure 3—figure supplement 1A). When purified PDE3B 
was incubated with the same amount of recombinant TBK1 and canonical IKKβ kinases in vitro, phos-
phorylation of PDE3B by IKKβ was barely detectable, indicating a level of specificity in which PDE3B is 
Figure 2. Prolonged treatment with TNFα decreases the sensitivity of adipocytes to β-adrenergic stimulation in a 
manner dependent on the activity of IKKε and TBK1. (A) Glycerol release from 3T3-L1 adipocytes treated with or without 
different concentrations of TNFα as indicated for 24 hr followed by treatment with or without 10 μM ISO or 50 μM FSK. 
**p<0.0001. Performed in quadruplicate. (B) cAMP levels from 3T3-L1 adipocytes treated with or without 100 ng/ml 
TNFα for 24 hr followed by treatment with or without 10 μM ISO or 50 μM FSK in the presence or absence of 
pretreatment of 50 μM Amlexanox (Am). **p<0.0001. Performed in quadruplicate. (C) cAMP levels from 3T3-L1 
adipocytes treated with or without 100 ng/ml TNFα for 24 hr followed by treatment with or without 50 μM FSK in the 
presence or absence of pretreatment of 1 μM CAY10576 (CAY). **p<0.0001. Performed in triplicate. (D) Immunoblots of 
whole cell lysates from 3T3-L1 adipocytes treated with or without different concentrations of TNFα as same as Figure 2A 
for 24 hr followed by treatment with or without 10 μM ISO or 50 μM FSK. Results were replicated in multiple experiments. 
‘[’ indicates total HSL. ‘n.s.’ represents non-specific band. Arrow indicates CGI-58. (E) Immunoblots of whole cell 
lysates from 3T3-L1 adipocytes treated with or without 50 ng/ml TNFα or 100 μg/ml poly (I:C) for 24 hr followed by 
treatment with or without 10 μM ISO for 15 min in the presence or absence of pretreatment with increasing 
concentrations (0, 10, 50, and 200 μM) of amlexanox for 30 min. Results were replicated in multiple experiments.
DOI: 10.7554/eLife.01119.005
The following figure supplements are available for figure 2:
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a better target of the noncanonical IKKs (Figure 3—figure supplement 1B). This phosphorylation was 
dose-dependent with respect to ATP (Figure 3—figure supplement 1C).
To determine whether IKKε can phosphorylate PDE3B in cells, we co-expressed IKKε and its inactive 
mutant K38A with HA-tagged PDE3B in HEK293T cells, followed by immunoprecipitation (IP) with 
anti-HA antibodies. Expression of IKKε in cells caused a shift in electrophoretic mobility of PDE3B, and 
Figure 3. IKKε and TBK1 reduce cAMP levels through activation of PDE3B. (A) cAMP levels from 3T3-L1 adipocytes 
expressing empty vector, Flag-IKKε, or Flag-TBK1 treated with or without 50 μM FSK, 250 μM IBMX, or together for 
15 min. *p<0.05 and **p<0.0001. Performed in duplicate. (B) cAMP levels from 3T3-L1 adipocytes expressing empty 
vector, Flag-IKKε, or Flag-TBK1 treated with or without 10 μM ISO or 50 μM FSK together with or without 10 μM 
Zardaverine (Zarda) for 15 min. *p<0.05. Performed in duplicate. (C) 32P phospho-image of in vitro kinase reaction 
using either immunoprecipitated HA-PDE3B from HEK293T cells or 1 μg MBP (myelin basic protein) as a substrate 
with recombinant kinases as indicated. Results were replicated in multiple experiments. (D) Immunoblots of 
immunoprecipitation with anti-HA antibodies followed by treatment with or without CIP (top panel) and whole cell 
lysates (bottom panel) from Cos-1 cells co-expressing HA-PDE3B with Flag-IKKε/TBK1 or Flag-IKKε/TBK1 K38A. 
D.E. stands for dark exposure and L.E. stands for light exposure. Results were replicated in multiple experiments. 
(E) Immunoblots of GST-14-3-3 pulldown from HEK293T cells co-expressing HA-PDE3B with Flag-TBK1 or Flag-
TBK1 K38A. Ponceau S staining shows the amount of beads used in GST-14-3-3 pulldown. Results were replicated 
in multiple experiments.
DOI: 10.7554/eLife.01119.007
The following figure supplements are available for figure 3:
Figure supplement 1. IKKε and TBK1 interact with PDE3B in a manner dependent on the activity of IKKε and TBK1. 
DOI: 10.7554/eLife.01119.008
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this shift was not detected when IKKε K38A was expressed (Figure 3—figure supplement 1D). 
Phosphorylation of PDE3B was also detected after expression of IKKε but not its kinase-inactive mutant 
K38A in cells, as detected by blotting with antibodies that recognize the 14-3-3 binding motif. To 
determine whether this molecular shift was dependent on phosphorylation of PDE3B, HA-PDE3B was 
co-expressed in Cos-1 cells along with IKKε, TBK1 or their kinase inactive mutants, and HA immuno-
precipitates were treated with or without calf intestinal phosphatase (CIP). Expression of both of the 
wild-type kinases reduced the electrophoretic mobility of PDE3B, which could be reversed by treatment 
with the phosphatase (Figure 3D, compare lane 3, 7 to lane 4, 8). Neither of the kinase-inactive 
mutants had an effect (Figure 3D, compare lane 5, 9 to lane 6, 10).
Previous studies suggested that IKKε and TBK1 bind to their respective substrates through a 
sequence that includes a ubiquitin-like domain (ULD) proximal to their kinase domain. This domain is 
highly conserved among the IKK family members, and is 49% identical between IKKε and TBK1 
(Ikeda et al., 2007; May et al., 2004). To confirm that PDE3B is a bona fide substrate of IKKε and 
TBK1, we prepared a GST-ULD domain fusion protein from TBK1 and incubated this fusion protein 
with 3T3-L1 adipocyte lysates. The fusion protein specifically precipitated endogenous PDE3B from 
these lysates (Figure 3—figure supplement 1E). To explore further the interaction of these two 
proteins, we co-expressed WT TBK1 and its K38A mutant with HA-tagged PDE3B in HEK293T cells, 
and immunoprecipitated the protein with anti-HA antibodies. Kinase-inactive TBK1 was preferentially 
co-immunoprecipitated with PDE3B, whereas the interaction of PDE3B with WT TBK1 was barely 
detectable (Figure 3—figure supplement 1F). These data suggest that TBK1 and IKKε associate with 
substrates such as PDE3B, and subsequently dissociate upon phosphorylation.
Next, to test further the role of PDE3B phosphorylation by IKKε and TBK1 in initiating its interaction 
with 14-3-3β, we prepared a GST-14-3-3β fusion protein which was incubated with lysates from 
HEK293T cells co-expressing TBK1 with PDE3B. PDE3B was preferentially pulled down by GST-14-3-
3β after phosphorylation by TBK1 but not by its inactive K38A mutant, whereas GST beads alone 
enriched neither PDE3B nor its phosphorylated form (Figure 3E).
IKKε and TBK1 phosphorylate PDE3B at serine 318, resulting in the 
binding of 14-3-3β
To evaluate the regulatory role of PDE3B phosphorylation by IKKε and TBK1, we determined which 
sites are phosphorylated. HA-PDE3B was co-expressed in Cos-1 cells with IKKε and TBK1, and phos-
phorylated PDE3B was enriched by IP with anti-HA antibodies. Phosphorylation sites on human PDE3B 
were then determined by LC-MS/MS mass spectrometry. This analysis revealed that serines 22, 299, 
318, 381, 463, 467, and 503 were phosphorylated by both kinases; there were no differences between 
the kinases (Figure 4A). Interestingly, the phosphorylation profile of PDE3B matched neither known 
Akt or PKA profiles (Lindh et al., 2007). However, phosphorylation on serine 299 and serine 318 had 
previously been identified on mouse PDE3B (residues equivalent to Serine 277 and 296 in mouse 
PDE3B) in adipocytes and hepatocytes in response to both insulin and forskolin (Lindh et al., 2007).
While several serine residues are known to be phosphorylated on PDE3B in response to stimuli, serine 
318 (human) is the best characterized. This residue resides in a consensus phosphorylation sequence 
for both Akt and PKA, and also serves as a consensus 14-3-3 binding motif once phosphorylated 
(Lindh et al., 2007; Palmer et al., 2007). We thus created a Ser318Ala (S318A) mutant of PDE3B, and 
examined its interaction with a GST-14-3-3β fusion protein or by GST-14-3-3 overlay assay. Interestingly, 
despite incubation with TBK1, the phospho-defective, S318A mutant of PDE3B, did not specifically interact 
with GST-14-3-3β, whereas the wild-type protein did (Figure 4B,C). In a GST pull-down assay, the molecular 
shift of PDE3B S318A was still detected by western blot (Figure 4B), indicating that phosphorylation of 
PDE3B by TBK1 on other sites still occurred, but were not crucial for 14-3-3β binding.
To examine the functional importance of the phosphorylation of PDE3B at Serine 318, we overex-
pressed WT PDE3B and its S318A mutant in 3T3-L1 adipocytes, and tested the response of the cells 
to TNFα. Overexpression of WT PDE3B in cells reduced the attenuation of forskolin-stimulated cAMP 
production and phosphorylation of HSL produced by TNFα, whereas PDE3B S318A was ineffective 
(Figure 4D, Figure 4—figure supplement 1A,B). These data suggest that although IKKε and TBK1 
can phosphorylate PDE3B on several sites, serine 318 may be particularly important in the regulation 
of phosphodiesterase function by promoting the interaction between PDE3B and 14-3-3β. More 
importantly, this residue is the major site mediating the negative effects of IKKε and TBK1 on sensitivity 
of adipocytes to β-adrenergic stimulation.
Cell biology
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The IKKε/TBK1 inhibitor Amlexanox sensitizes β-adrenergic agonist-
stimulated lipolysis in white adipose tissue in diet-induced obese mice
Disruption of sympathetic activation of lipolysis and fat oxidation may play an important role in the 
development and maintenance of increased fat storage in obesity. Indeed, while numerous studies 
have demonstrated catecholamine resistance in obese adipose tissue (Jensen et al., 1989; Reynisdottir 
et al., 1994; Bougneres et al., 1997; Arner, 1999; Jocken and Blaak, 2008), the underlying mecha-
nisms remain unclear. To test the functional importance of the noncanonical IKKs in maintaining energy 
balance in vivo, we investigated whether the administration of a selective inhibitor of IKKε and TBK1, 
amlexanox, can reverse diet-induced catecholamine resistance in rodents. We fed mice a high fat or 
normal diet, treated them with amlexanox by oral gavage for 4 days (prior to the point when weight 
loss is seen), and then gave a single intraperitoneal (IP) injection of the β3-adrenergic agonist CL-316,243. 
Injection of CL-316,243 stimulated a threefold increase in serum FFA and glycerol levels in both vehicle 
and amlexanox-treated mice on normal diet (ND). The effect of CL-316,243 to increase serum FFAs 
was significantly attenuated in HFD-fed, vehicle-treated mice. However, HFD-fed mice treated with 
Figure 4. IKKε and TBK1 phosphorylate PDE3B at serine 318, resulting in the binding of 14-3-3β. (A) Summary of 
sites on PDE3B phosphorylated by IKKε or TBK1 (P-sites) from mass spectrometry experiments. (B) Immunoblots of 
GST-14-3-3 pulldown from HEK293T cells co-expressing HA-PDE3B or HA-PDE3B S318A with Flag-TBK1. Ponceau S 
staining shows the amount of beads used in GST-14-3-3 pulldown. Results were replicated in multiple experiments. 
(C) GST-14-3-3 overlay on nitrocellulose membrane (top blot) and an immunoblot (IB) of whole cell lysates from 
HEK293T cells co-expressing HA-PDE3B or HA-PDE3B S318A with Flag-TBK1 (bottom blot). Results were replicated 
in multiple experiments. (D) cAMP levels from 3T3-L1 adipocytes expressing empty vector, HA-PDE3B, or HA-PDE3B 
S318A treated with or without 100 ng/ml TNFα for 16 hr followed by treatment with or without 25 μM FSK for 15 min. 
**p<0.0001 and **p<0.01. Performed in duplicate.
DOI: 10.7554/eLife.01119.009
The following figure supplements are available for figure 4:
Figure supplement 1. Overexpression of PDE3B in 3T3-L1 adipocytes reduces the attenuation of forskolin-stimulated 
β-adrenergic signaling produced by TNFα. 
DOI: 10.7554/eLife.01119.010
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amlexanox responded like normal diet mice, despite the fact that they were weight matched with 
control HFD-fed mice (Figure 5A). The fold increase in serum glycerol levels was also significantly higher 
in amlexanox-treated HFD mice, as compared to vehicle-treated HFD-fed mice. In addition, ex vivo 
pretreatment of white adipose tissues from mice on a HFD with amlexanox enhanced glycerol release 
(Figure 5B). This effect was more pronounced in the inguinal fat depot, where amlexanox pretreatment 
increased phosphorylation of HSL, perilipin, and other proteins recognized by the PKA substrate motif 
antibody in response to CL-316,243 treatment compared to vehicle-pretreated tissues (Figure 5C). 
Amlexanox also concurrently increased the phosphorylation of TBK1 at Ser172 due to the relief of feed-
back inhibition, as previously reported with other inhibitors (Clark et al., 2009; Reilly et al., 2013).
Figure 5. The IKKε/TBK1 inhibitor Amlexanox sensitizes β-adrenergic agonist-stimulated lipolysis in white adipose 
tissue in diet-induced obese mice. (A) Fold increase in serum FFA (left panel) and glycerol (right panel) levels 15 
min after CL-316,243 injection in ND- or HFD-fed mice treated with amlexanox or vehicle control for 4 days. n = 7 mice 
per group. *p<0.05. (B) Glycerol release from ex vivo epididymal (left panel) and inguinal (right panel) WATs after 1 hr 
pretreatment with amlexanox or vehicle. CL-316,243 treatment was started at time zero. n = 6, 3 WAT pieces × 2 mice. 
*P<0.05. (C) Immunoblots in inguinal WAT lysates from Figure 5B after 60 min of CL-316,243 treatment. (D) cAMP 
levels in epididymal WAT 20 min after CL-316,243 (CL) or saline control injection in HFD-fed mice treated with 
amlexanox or vehicle control for 4 days. n = 2 mice per saline-treated group and n = 3 mice per CL-316,324-treated 
group. *p<0.05. (E) Immunoblots in epididymal WAT 5 min after CL-316,243 or saline control injection in HFD-fed mice 
treated with amlexanox or vehicle control for 4 days. (F) Relative oxygen comsumption of mice in each treatment 
group. n = 7 for the vehicle-treated group, n = 5 for the amlexanox-treated group. *P<0.05 (Student’s t test).
DOI: 10.7554/eLife.01119.011
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To examine whether inhibition of TBK1 and IKKε with amlexanox reverses resistance to catecholamine-
induced lipolysis in vivo by increasing stimulation of cAMP production, we measured cAMP levels in 
epididymal adipose tissue from mice on HFD after CL-316,243 IP injection. Interestingly, levels of cAMP 
were increased after CL-316,243 IP injection in mice on HFD pretreated with amlexanox (Figure 5D). 
Consistent with this, HSL phosphorylation was also increased after CL-316,243 IP injection of HFD-fed 
mice pretreated with amlexanox (Figure 5E).
Our previous studies showed that increased expression of Ucp1 in white adipose depots resulted 
in increased energy expenditure in IKKε-deficient mice (Chiang et al., 2009) and amlexanox-treated 
mice (Reilly et al., 2013) while on a high fat diet but not on a normal diet. To examine whether inhibition 
of catecholamine resistance in obese adipose tissue by targeting noncanonical IKKs with amlexanox 
can lead to increase energy expenditure in diet-induced obese mice, we measured oxygen consumption 
rates of vehicle or amlexanox-treated HFD-fed mice after a single injection of CL-316,243 in metabolic 
cages. The effect of CL-316,243 to increase energy expenditure was more pronounced in amlexanox-
treated HFD-fed mice, as compared to vehicle-treated HFD-fed mice (Figure 5F). These data suggest 
that targeting the noncanonical IKKs with the selective inhibitor amlexanox ameliorated catecholamine 
resistance in obese adipose tissue.
Discussion
Decreased sympathetic activation of adipose tissue due to impaired catecholamine synthesis or sensitivity 
has been observed in obese patients (Reynisdottir et al., 1994; Stallknecht et al., 1997; Horowitz 
and Klein, 2000; Jocken et al., 2008). Obesity is commonly associated with blunted whole-body 
catecholamine-induced lipolysis (Horowitz and Klein, 2000). This is thought to occur through a number of 
mechanisms, including leptin resistance (Myers et al., 2010), as well as the reduced expression of 
β-adrenergic receptors (Reynisdottir et al., 1994) or increased expression of α2-adrenergic receptors 
(Stich et al., 2002). White adipose tissue and cultured isolated adipocytes from obese human and 
mouse models exhibit decreased cAMP-stimulated lipolysis and fat oxidation, due to reduced energy 
expenditure from decreased mitochondrial uncoupling (Yehuda-Shnaidman et al., 2010). This desensitiza-
tion to adrenergic activation is also a feature of childhood onset obesity (Bougneres et al., 1997; 
Enoksson et al., 2000), and has been observed in adipocytes from first-degree relatives of obese 
subjects (Hellstrom et al., 1996).
We demonstrate here a novel link between obesity and reduced sympathetic activity and β-adrenergic 
sensitivity, through the inflammation-dependent induction of the noncanonical IκB kinases IKKε and 
TBK1. Obesity generates a state of low-grade inflammation in both humans and rodents, which 
involves activation of the NFκB pathway (Wellen and Hotamisligil, 2005; Hotamisligil, 2006; Shoelson 
et al., 2007). Upon its prolonged activation, NFκB induces the expression of the noncanonical IκB 
kinases IKKε and TBK1. The induction of these kinases was blocked by administration of anti-inflammatory 
agents to mice without producing weight loss, suggesting that they are expressed in response to inflam-
mation rather than obesity per se (Reilly et al., 2013). Deletion of the IKKε gene rendered mice partially 
resistant to weight gain, insulin resistance, steatosis and the long-term inflammation produced by high 
fat diet (Chiang et al., 2009), and administration of the dual specificity IKKε/TBK1 inhibitor amlexanox 
to diet-induced obese or ob/ob mice produced even more profound effects (Reilly et al., 2013). The 
blockade of these kinases in obese rodents with amlexanox results in increased phosphorylation of 
PKA substrates in adipose tissue, along with increased expression of Ucp1, and improved rates of 
lipolysis and fat oxidation (Reilly et al., 2013). Amlexanox was shown to inhibit phosphodiesterase 
activity of rat peritoneal mast cells via an unknown mechanism (Makino et al., 1987). Together these 
data indicate that IKKε and TBK1 might exert their physiological effects in part by reducing the sensitivity 
of adipocytes to β-adrenergic stimulation via changes in cAMP.
Data presented here suggest that the molecular target of IKKε/TBK1 is the phosphodiesterase 
PDE3B. Upon increased expression in the obese state, these kinases can phosphorylate PDE3B, causing 
an increase in the activity of the enzyme that cleaves cAMP, reducing the stimulation of cAMP-dependent 
phosphorylation of proteins in response to sympathetic activation. These proteins include HSL and 
perilipin, responsible for β-adrenergic-stimulated lipolysis, and other proteins such as p38 that regulate 
expression of Ucp1. The reduced sensitivity to β-adrenergic activation can attenuate lipolysis and fatty 
acid oxidation, as well as adaptive thermogenesis.
Several issues deserve further attention. The first concerns the relative roles of the two noncanonical 
IKKs in this pathway. Both TBK1 and IKKε are induced in response to obesity-dependent inflammation, 
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and appear to phosphorylate PDE3B on the same residues with equal efficiency. Although there 
are differences in expression of these kinases in other tissues (Shimada et al., 1999), and perhaps 
differences in the upstream signals that lead to their regulation (Wunderlich et al., 2008), their relative 
roles in controlling this pathway remain uncertain. Additionally, the mechanism by which PDE3B is 
regulated remains uncertain. While phosphorylation correlates well with decreased levels of cAMP 
in cells, we have been unable to demonstrate increased catalytic activity of the enzyme due to phos-
phorylation by IKKε, TBK1 or the other kinases (Kitamura et al., 1999; Palmer et al., 2007) thought 
to regulate the phosphodiesterase. Perhaps the phosphorylation-dependent binding of the enzyme 
to 14-3-3 exerts changes in its localization and access to its substrate, thus explaining increased 
activity in cells.
How is it that insulin resistance produced by inflammation fails to block continued energy storage? 
One possible explanation may lie in the homeostatic response to inflammation itself, typified by the 
induction of TBK1 and IKKε. Our data confirm previous findings that TNFα and perhaps other inflam-
matory cytokines can promote lipolytic processes in cells after short-term treatment, but that after 
longer exposure elicit an inhibitory response that appears to be the result of TBK1 and IKKε induction. 
Thus, these kinases may be part of a ‘counter-inflammatory’ program that attenuates the extent to 
which inflammatory signals are effective, and also serves to conserve energy by repressing lipolysis and 
fatty acid oxidation through activation of PDE3B. Interestingly, PDE3B is also a target of insulin action 
in adipocytes (Degerman et al., 2011). Thus, TBK1 and IKKε appear to co-opt insulin targets to 
conserve energy during obesity. These insights further suggest that the noncanonical IKKs might be 
interesting new therapeutic targets for the treatment of obesity and type 2 diabetes.
Materials and methods
Reagents
All chemicals were obtained from Sigma-Aldrich (Saint Louis, MO) unless stated otherwise. Anti-Flag 
antibody was obtained from Sigma, and anti-HA antibody was obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA). Anti-IKKε, anti-TBK1, anti-phospho-TBK1 (Ser172), anti-AKT, anti-phospho-AKT (Ser473), 
anti-HSL, anti-phospho-HSL (Ser660), anti-p38, anti-phospho-p38, anti-perilipin, anti-ATGL and anti-PPARγ 
antibodies were purchased from Cell Signaling Technology (Danvers, MA). Anti-phospho-perilipin 
(Ser522) was purchased from Vala Sciences Inc (San Diego, CA). Anti-CGI-58 was purchased from 
Novus Biologicals (Littleton, CO). Anti-RalA antibody was obtained from BD Bioscience (San Jose, CA). 
Anti-Ucp1 antibody was obtained from Alpha Diagnostics (San Antonio, TX). Anti-PDE3B was provided 
as a generous gift by the Dr Vince Manganiello (NHLBI, NIH). Enhanced chemiluminescence (ECL) 
reagents were purchased from Thermo Scientific (Rockford, IL). EDTA-free protease inhibitor tablet 
was purchased from Roche Diagnostics (Indianapolis, IN). Monoclonal anti-HA agarose (Sigma) was 
used for immunoprecipitations, performed using the manufacturer’s protocol. The human PDE3B 
cDNA was kindly provided by Dr Morris Birnbaum (University of Pennsylvania). The human 14-3-3β 
cDNA was kindly provided by Dr Ken Inoki (University of Michigan) and subcloned into pKH3 (Chen 
et al., 2007) and pGEX-4T-1 vectors (GE Healthcare Life Sciences, MI). Amlexanox was purchased 
from Ontario Chemical Inc. (Guelph, Ontario, Canada). The TBK1/IKKε inhibitor CAY10576 was pur-
chased from Cayman Chemical (Ann Arbor, MI).
Cell culture and transfection
3T3-L1 fibroblasts (American Type Culture Collection, Manassas, VA) were cultured and differentiated 
as described previously (Liu et al., 2005). The cells were routinely used within 7 days after completion 
of the differentiation process; only cultures in which >90% of cells displayed adipocyte morphology 
were used. 3T3-L1 adipocytes were transfected on the second day post FBS using Amaxa Cell Line 
Nucleofector Kit L (Lonza, Houston, TX) according to the manufacturer’s protocol. 3T3-L1 adipocytes 
were serum starved for 12 hr with 0.5% fetal bovine serum (FBS) in Dulbecco’s modified eagle medium 
(DMEM, Invitrogen, Grand Island, NY) prior to TNFα treatments (50 ng/ml unless otherwise noted). 
3T3-L1 adipocytes were pre-treated for 1 hr with amlexanox at the given concentrations. Alternatively, 
3T3-L1 adipocytes were treated with 50 μM forskolin or 10 μM isoproterenol for 15 min, after a 60 min 
amlexanox pretreatment. The cells were harvested for total RNA and analyzed by real-time PCR. Cell 
lysates were resolved on SDS-PAGE and analyzed by immunoblot using the indicated antibodies. 
HEK293T or Cos-1 cells were cultured to 90% confluence and transfected using Opti-MEM media 
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(Invitrogen) and 3 μl Lipofectamine 2000 (Invitrogen) per μg DNA according to manufacturer’s 
protocol. Coexpression of IKKε or TBK1 with HA-PDE3B was done using a 2 μg kinase: 1 μg PDE3B 
ratio of the expression constructs.
Western analyses
Tissues were homogenized in lysis buffer (50 mM Tris, pH 7.5, 5 mM EDTA, 250 mM sucrose, 1% NP40, 
2 mM DTT, 1 mM sodium vanadate, 100 mM NaF, 10 mM Na4P2O7, and freshly added protease inhib-
itor tablet), then incubated for 1 hr at 4°C (Chiang et al., 2009). Crude lysates were then centrifuged 
at 14,000 × g for 15 min twice and the protein concentration was determined using BioRad Protein 
Assay Reagent (Bio-Rad, Hercules, CA). Samples were diluted in sodium dodecyl sulfate (SDS) sample 
buffer and boiled for 5 min at 95°C. Proteins were resolved by SDS-polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). Individual proteins were detected 
with the specific antibodies and visualized on film using horseradish peroxidase-conjugated secondary 
antibodies (Bio-Rad, Hercules, CA) and Western Lightning Enhanced Chemiluminescence (Perkin 
Elmer Life Sciences, Waltham, MA).
Animals and animal care
Wild-type male C57BL/6 mice were fed a high fat diet consisting of 45% of calories from fat (D12451 
Research Diets Inc., New Brunswick, NJ) starting at 8 weeks of age for up to 6 months, while normal 
diet C57BL/6 controls were maintained on normal chow diet consisting of 4.5% fat (5002 Lab Diet, 
St. Louis, MO). Animals were housed in a specific pathogen-free facility with a 12-hr light/12-hr dark 
cycle and given free access to food and water. All animal use was in compliance with the Institute of 
Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and approved by the 
University Committee on Use and Care of Animals at the University of Michigan.
Gene expression analysis
Total RNA was extracted from differentiated 3T3-L1 adipocytes using the RNeasy Kit (Qiagen, Valencia, 
CA) with a DNase step. The Superscript First-Strand Synthesis System for RT-PCR (Invitrogen, Grand 
Island, NY) was used with random primers for reverse transcription. Real-time PCR amplification of the 
cDNA was performed on samples in triplicate with Power SYBR Green PCR Master Mix (Applied 
Biosystems, Carlsbad, CA) using the Applied Biosystems 7900HT Fast Real-time PCR System. Adrp 
was chosen as the internal control for normalization as its expression was not significantly affected by 
experimental conditions. Sequences of Ucp1 primers used in this study are 5′-AGGCTTCCAGTA
CCATTAGGT‐3′ and 5′‐CTGAGTGAGGCAAAGCTGATTT‐3′. Sequences of Ikbke primers used in this 
study are 5′-ACAAGGCCCGAAACAAGAAAT-3′ and 5′-ACTGCGAATAGCTTCACGATG‐3′. Data were 
analyzed using the 2−ΔΔCT method (Livak and Schmittgen, 2001).
In vivo CL-316,243 treatment
Mice were placed on a high fat diet for 6 months, then after 1 week of daily gavage with vehicle, mice 
were gavaged with either vehicle or amlexanox (25 mg/kg) daily for 4 days. On the fourth day, mice 
were injected with CL-316,243 (1 mg/kg) or saline control. For analysis of blood metabolites, serum 
samples were collected before and 15 min after the injection, via a submandibular bleed. Mice were 
euthanized and WAT samples were collected for cAMP measurement and western blot analysis, 15 min 
or 20 min after injection. Analysis of oxygen consumption was performed in metabolic cages, as 
previously described (Reilly et al., 2013), by the University of Michigan Metabolic Phenotyping Core. 
Relative oxygen consumption was obtained by normalization of oxygen consumption rates, after the 
CL-316,243 injection, to the oxygen consumption rates on day 3 in the same mouse after saline injec-
tion. Both injections were performed at 11 am.
Ex vivo glycerol release lipolysis assay in white adipose tissue
For experiments involving CL-316,243, pieces were pre-incubated for 30 min with amlexanox (100 μM) 
or DMSO vehicle control; then the tissue pieces were transferred to fresh media with and without 
10 mM CL-316,243, and media samples were collected every 15 min for 1 hr. To measure glycerol 
release, 10 μl of supernatant was combined with 200 μl of Free Glycerol Reagent from the Free Glycerol 
Determination Kit (Sigma) and allowed to incubate for 15 min at room temperature. Absorbance at 
540 nm was measured to determine glycerol content and was normalized to determine glycerol pro-
duction per mg of white adipose tissue.
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Glycerol release lipolysis assay in 3T3-L1 adipocytes
3T3-L1 adipocytes were incubated in DMEM (Invitrogen) without phenol red for 2 hr at 37°C. The cells 
then were incubated for 90 min at 37°C in HBSS-2% fatty acid-free BSA with 10 μM isoproterenol or 
10 μM CL-316,243. Free glycerol concentration was measured by reacting 25 μl of conditioned media 
with 200 μl Free Glycerol Reagent (Sigma) and absorbance was measured at 540 nm using the manu-
facturer’s protocol. Glycerol release was normalized to cellular protein content.
cAMP enzyme immunoassay
3T3-L1 adipocytes were treated with β-agonists and/or phosphodiesterase inhibitors and allowed to 
incubate for the indicated amount of time at 37°C. The cells were lysed with 150 μl 0.1 M HCl, scraped 
and spun down. A cAMP Enzyme Immunoassay Kit (Sigma CA201) was used to quantify cAMP levels. 
50 μl of cell lysates was combined with 50 μl Assay Buffer 2 in each well and cAMP levels were assayed 
according to the manufacturer’s protocol. Tissue samples were homogenized in 5% TCA, then 
extracted with water-saturated ether, and dried before resuspension in Assay Buffer 2.
Glosensor cAMP assay in 3T3-L1 adipocytes
80 μl of packed 3T3-L1 cells was electroporated with 3 μg of Glosensor 22-F using Amaxa Cell Line 
Nucleofector Kit L (Lonza) according to the manufacturer’s protocol. Electroporated cells were resus-
pended in 10 ml of L1-FBS media and 200 μl per well was plated in six columns of an opaque, white, 
96-well tissue culture plate (BD Bioscience, San Jose, CA). After 20 hr, media were changed to 100 μl 
DMEM with 1.5 mg/ml luciferin and allowed to equilibrate for 1 hr. The cells were treated with 50 μM 
forskolin and luminescence was read every 30 s for 75 min.
In vitro kinase assays
In vitro kinase assays were performed by incubating purified kinase (IKKε, TBK1, IKKβ, PKA, or 
AKT) in kinase buffer containing 25 mM Tris (pH 7.5), 10 mM MgCl2, 1 mM DTT, and 10 μM ATP 
for 30 min at 30°C in the presence of 0.5 μCi γ-[32P]-ATP and 1 μg myelin basic protein (MBP) per 
sample as a substrate. IKKε and TBK1 were fused to MBP (maltose binding protein) and these fusion 
proteins were purified from insect SF9 cells by baculovirus expression system by Dr Stuart J Decker 
(Life Sciences Institute, University of Michigan). IKKβ, PKA, and AKT kinases were purchased from 
Millipore (Billerica, MA). The kinase reaction was stopped by adding 4X sodium dodecyl sulfate 
(SDS) sample buffer and boiling for 5 min at 95°C. Supernatants were resolved by SDS-polyacrylamide 
gel electrophoresis, transferred to nitrocellulose, and analyzed by autoradiography using a 
Typhoon 9410 phosphorimager (GE Life Sciences, Piscataway, NJ). The bands were quantified 
using ImageQuant.
Calf-intestinal phosphatase dephosphorylation
Calf intestinal phosphatase (CIP) was obtained from New England Biolabs (Ipswich, MA). 
Immunoprecipitated PDE3B was incubated for 1 hr at 37°C in a 100 μl reaction containing 50 mM Tris 
pH 7.5, 150 mM NaCl, 1% NP-40, EDTA-free protease, and 5 μl CIP.
Protein purification
For assays requiring soluble protein, purified GST-14-3-3β protein was eluted from glutathione beads 
by washing beads with 10 mM glutathione in PBS, pH 8.0. The elution was monitored by A280 readings, 
and fractions containing protein were pooled and dialyzed overnight against 4 L of ice-cold PBS. The 
proteins were then concentrated using an Amicon centrifugal filtration unit (Millipore). Concentrated 
proteins were stored at −80°C in PBS containing 10% glycerol and 10 mM DTT.
GST-14-3-3 Pulldown
For GST-14-3-3 pulldowns, cells were washed twice with ice-cold PBS and then lysed in 1 ml of 14-3-3 
pulldown buffer (PD buffer; 15 mM Tris, pH 7.5, 150 mM NaCl, 0.5% NP-40, 1 mM DTT) supplemented 
with a protease inhibitor tablet (Roche). Lysates were cleared by centrifuging at 13,000×g for 10 min 
and then were incubated with ∼10 mg of GST or GST-14-3-3β bound to glutathione beads (GE 
Healthcare Life Sciences, MI) for 1.5 hr at 4°C. For samples treated with phosphatase, lysates were 
preincubated with 500 U of calf intestinal phosphatase (New England Biolabs, Inc.) at 37°C for 1 hr 
before adding GST-14-3-3 beads. The beads were washed three times with 1 ml of PD buffer and then 
resuspended in 2X SDS sample buffer.
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Preparation of DIG-labeled proteins and overlay assay
GST or GST-14-3-3β was labeled with DIG by incubating 25 mg of protein with 2 ml of 5 mM 
Digoxigenin-3-O-methylcarbonyl-ε-aminocaproic acid-N-hydroxysuccinimide ester (DIG-NHS; Roche) 
in 350 ml of PBS for 15 min at room temperature. The labeling reaction was stopped by adding 100 ml 
of 1 M Tris-HCl, pH 7.4. Labeled protein was dialyzed against 1 L of 25 mM Tris-HCl, pH 7.4 for 1 hr at 
room temperature, then against 4 L of PBS, pH 7.4 for 4 hrs at 4°C, and finally against 4 L of fresh PBS, 
pH 7.4 for 16 hrs at 4°C. Labeled protein was then diluted in 25 ml of TBS (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl) containing 2 mg/ml BSA (Sigma-Aldrich) and 0.01% sodium azide (Sigma-Aldrich). 
DIG-labeled proteins were stored at 4°C.
For overlay assays, PDE3B was immunoprecipitated from HEK293T cells and resolved by SDS-
PAGE. Proteins were transferred to a nitrocellulose membrane. The membrane was blocked at 
room temperature overnight in blocking buffer (5% skim milk in TBS-T). The membrane was then 
incubated with DIG-labeled proteins for at least 4 hr at 4°C and then washed three times with 
TBS-T. The membrane was then incubated with blocking buffer containing anti-DIG HRP antibody 
(1:10,000; Roche) for 2 hr at room temperature, and washed three times with TBS-T. Overlays were 
visualized by reacting with ECL western blotting substrate (Perkin Elmer Life Sciences, Waltham, 
MA).
Mass spectrometry
In-gel digestion followed by LC-MS/MS analysis was carried out by the mass spectrometry-based 
proteomics resource in the Department of Pathology, University of Michigan. Briefly, tryptic pep-
tides were resolved on a nano-C18 reverse phase column and sprayed directly onto Orbitrap mass 
spectrometer (LTQ-Orbitrap XL, Thermofisher). Orbitrap was operated in a data-dependent mode 
to acquire one full MS spectrum (resolution of 30,000@400 m/z) followed by MS/MS spectra on six 
most intense ions (top 6). Proteins were identified by searching data against human protein data-
base (Uniprot, rel. 2010-9) using X!Tandem/TPP software suite. Oxidation of Met, carbamidometh-
ylation of Cys and phosphorylation of Ser, Thr, and Tyr were considered as potential modifications 
(Maine et al., 2010).
Statistical analyses
Averaged values are presented as the mean ± SEM. When comparing two groups, we performed 
Student’s t test to determine statistical significance. When more than two groups and two factors were 
investigated, we first performed a two-way analysis of variance (ANOVA) to establish that not all 
groups were equal. After a statistically significant ANOVA result, we performed between-group 
comparisons using the Tukey post hoc analysis for comparisons of all means and Sidak for comparisons 
of within factor main effect means. ANOVA and Tukey/Sidak tests were performed using GraphPad 
Prism version 6.
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